forumNordic

Global Visibility for Nordic Innovations

AI STEPS INTO TOXICOLOGY – Norwegian Researchers Use Machine Learning to Predict Fentanyl Antidote Success

The opioid emergency meets algorithmic prediction

Norway is stepping into one of the world’s thorniest public‑health challenges with an unusual tool: machine learning models designed to forecast how well an antidote will work in a fentanyl overdose. At Norway Life Science 2026 in Oslo, veterinarian‑researcher Nora Digranes (NMBU) presented work on “Artificial intelligence as a tool to predict antidote efficacy in fentanyl overdose models,” signalling a shift from lab‑only pharmacology toward data‑driven toxicology that aims to guide real‑time clinical decisions.

The context is stark. While Norway’s opioid mortality has stayed broadly high but comparatively stable, opioids are implicated in 80–90% of overdose deaths domestically, an epidemiological pressure that keeps antidote strategies front and centre for emergency medicine and policymakers.

Beyond naloxone: why predicting efficacy matters

Naloxone remains the global standard for reversing opioid overdose. But fentanyl, and a widening family of ever‑changing analogues, has exposed the limits of a one‑drug‑fits‑all response. Norwegian researchers coordinating the AntiFENT project at NMBU describe a key complication: fentanyl can induce skeletal‑muscle activation (including “wooden chest” and vocal‑cord closure) that compromises ventilation, leaving patients hypoxic even after the classic opioid triad is pharmacologically reversed. AntiFENT’s preclinical work suggests that targeting the serotonin system (e.g., with ketanserin) alongside naloxone could counter these effects.

If clinical teams are to deploy such combination strategies under time pressure, they will need predictive tools: models that ingest patient signals (vital signs, blood gases), exposure proxies (scene data, suspected analogue), and treatment options (dose, route, second‑agent timing) to estimate the likelihood of reversal, and of sustained ventilation, after a given regimen. That is the promise behind bringing AI into toxicology: move from generalized protocols toward case‑specific predictions that can be audited and improved over time.

What the Norwegian teams are building

Although detailed model architectures were not public at the time of the conference, NMBU’s session and the AntiFENT documentation outline a translational pipeline: animal‑model physiology → mechanistic targets → candidate antidote pairings → data structures that encode dose‑response and time‑to‑recovery → predictive algorithms. The goal is not to replace clinical judgement but to rank likely effective countermeasures as the situation evolves, especially when fentanyl analogues complicate the picture.

Parallel Norwegian work underscores how AI toxicology is maturing. The Norwegian Institute of Public Health participates in ONTOX, a multi‑year European program to build AI‑driven “new approach methodologies” for repeated‑dose toxicity, integrating mechanistic maps, exposure models and adverse‑outcome pathways. While ONTOX isn’t opioid‑specific, it shows the institutional commitment to explainable, regulatory‑grade AI in safety science, exactly the governance scaffolding antidote‑prediction models will need.

AI already detects fentanyl! Can it guide treatment next?

Internationally, machine learning has been picking out fentanyl from complex signals with rising accuracy. Lawrence Livermore National Laboratory reported a >95% accurate random‑forest model that recognizes opioid signatures for analytical chemistry, while Science Advances showcased Fentanyl‑Hunter, a mass‑spectrometry classifier with an F1 ≈ 0.87 that mapped known and novel fentanyl’s and tracked metabolites in wastewater. These advances live upstream of the clinic, but they demonstrate how AI scales across noisy chemical spaces, a trait that antidote‑efficacy models will need when patients arrive with unknown analogues on board.

Even field‑level harm‑reduction has benefited: a PLOS One study trained a neural network on 12,684 FTIR spectra from British Columbia drug‑checking services, outperforming technicians (F1 96.4% vs. 78.4%) and recovering low‑concentration fentanyl cases, the exact edge conditions that complicate emergent care. Meanwhile, Los Alamos demonstrated that neural networks can denoise NQR signals to detect fentanyl in unopened packages, hinting at an end‑to‑end pipeline where supply‑chain detection and clinical prediction are both AI‑assisted.

Features, labels, and the right outcomes

To be clinically useful, an antidote‑efficacy model must predict outcomes that clinicians can act on, not just “survival,” but time to adequate ventilation, need for repeat dosing, risk of re‑narcosis, and probability of airway interventions. Norwegian preclinical data provide mechanistic priors (e.g., serotonin‑mediated muscle effects) that can be encoded as features or constraints within the model. In practice, this means fusing vital signs, capnography, blood gas proxies, time‑stamped naloxone/ketanserin dosing, and, where available, toxicology screens into a temporal model (e.g., survival analysis or sequence models) that estimates the delta in patient trajectory with and without adjunct therapy.

The labelling problem is non‑trivial. Ground truth in overdose care is messy: mixed‑drug exposures, variable prehospital ventilation quality, and incomplete confirmatory tox screens. That’s where Norway’s strengths are an advantage. The OUH overdose research group merges forensic toxicology with the Cause of Death Registry, enabling unusually granular linkage between drug findings and outcomes, ideal conditions for model training and audit.

Trust, explainability and regulatory‑grade AI

No hospital will deploy a black‑box tool at the sharp end of resuscitation. Norwegian researchers can draw on emerging validation frameworks (e.g., TREAT principles and “e‑validation” agendas) to ensure trustworthiness, reproducibility, explainability, applicability and transparency. A growing literature proposes argumentation‑driven explainable AI for medicine, where models generate human‑readable rationales for predictions rather than only scores. In overdose medicine, that could sound like: “Given observed hypoventilation, chest‑wall rigidity indicators, dosing history and time since exposure, predicted response to naloxone‑only is 58% within 6 minutes; adding ketanserin IV 10 mg raises probability to 77% with reduced risk of re‑rigidity.”.

Explainability also matters for generalization. Reviews of AI in toxicology caution that models trained on narrow datasets can overfit lab conditions, failing in the chaotic real world of poly‑substance use and comorbidities; clear model cards, uncertainty estimates, and post‑deployment surveillance (monitoring drift, bias audits) will be critical.

The fentanyl “moving target”: analogues, in silico hazard, and policy

A persistent headache is chemical novelty: thousands of fentanyl analogues exist, with toxicity profiles that can shift with minor structural tweaks. Recent in silico toxicology papers (e.g., on valerylfentanyl) show how QSAR ensembles predict organ‑system risks and cardiac liabilities—useful signals when prioritizing adjunct antidotes or monitoring plans. For prediction systems, these data can feed bayesian priors: when analogues exhibit a particular toxicophore pattern, models could nudge clinicians toward airway‑first strategies or adjunct choices beyond naloxone.

There’s also a dual‑use debate: the same chemical‑AI methods that can curb synthesis routes (by flagging or redesigning precursors) highlight the policy stakes around open models. Norway’s approach, pairing AI innovation with regulatory dialogue and clinical governance, may prove decisive in keeping research patient‑centric and safety‑first.

From conference talk to clinical tool

  1. Publish the models and datasets. Even de‑identified, open protocols and validation cohort’s matter. Norway can leverage the NVA repository, which already aggregates millions of research outputs and datasets nationally, to host reproducible pipelines and promote FAIR data for overdose research.
  2. Prospective trials in prehospital settings. The obvious proving ground is prehospital care (ambulance services), where time‑to‑ventilation predictions could triage between repeat naloxone vs. adjunct + airway management. Norway’s integrated emergency services and high autopsy rates make feedback loops (prediction → outcome → model update) feasible.
  3. Human‑in‑the‑loop design. Embedding explainable interfaces into monitoring devices (capnography, bag‑valve‑mask sensors) would let clinicians override or accept model suggestions, preserving accountability while building audit trails for regulators. Evidence from adjacent fields, AI triage for overdose survival, xAI for emergency management, can inform interface design and governance.
  4. Standards and certification. Norway’s participation in EU‑aligned medical‑AI regulation (risk classification, performance metrics, post‑market surveillance) should be planned in parallel with model iterations, not after the fact. That’s the lesson from broader AI‑toxicology frameworks: validation is a lifecycle, not a checkbox. 

What success would look like in 12–24 months

  • A published algorithm (or set of algorithms) predicting antidote efficacy with calibrated confidence intervals, trained on Norwegian preclinical + clinical data, with external validation partners.
  • Pilot deployment across selected prehospital units and EDs with go/no‑go criteria tied to safety and operational impact (e.g., reductions in time to adequate ventilation, fewer re‑narcosis events).
  • Open model cards documenting intended use, limitations, bias checks, and drift monitoring, referenced in the NVA to maximize transparency and re‑use.

If Norway pulls this off, it won’t just be a national story. It would mark one of the first instances where AI crosses the bridge from detecting a dangerous substance to actively guiding its treatment, a template that could extend to other toxidromes (e.g., xylazine co‑exposure, novel benzodiazepines), where off‑label or adjunctive therapies need data‑backed triage.

Sources & further reading

Share this post:

Share on LinkedIn

© 2024 forumNordic. All rights reserved. Reproduction or distribution of this material is prohibited without prior written permission. For permissions: contact (at) forumnordic.com